{"text":"Thirteen patients with chronic intraocular inflammation which had not been adequately controlled with oral prednisolone entered into an open study of low-dose Cyclosporin A ( mean 4.1 mg/kg/day ) combined when required with oral prednisolone ( 15 mg prednisolone per day or less ) .","paragraph":"<h3><u>Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation.</u></h3> <b style='color:DodgerBlue;'><i>Thirteen</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>intraocular</i></b> <b style='color:DodgerBlue;'><i>inflammation</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>adequately</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>entered</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>open</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>Cyclosporin</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>4.1</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The mean duration of treatment was 26 months (range 8-44) over a mean follow-up period of 29 months (range 8-49). Visual acuity improved overall in ten patients, and remained stable in three. Six patients have completed a course of Cyclosporin A therapy, and four of these patients have retained their visual improvement. Two have returned to the pretreatment level of vision. Only one patient has required conversion to alternative immunosuppressive therapy. The mean serum creatinine concentration had increased significantly by 26% after six months (p less than 0.05) and 32% after one year (p less than 0.01) but remained stable during the subsequent 18 months. Four patients developed hypertension requiring hypotensive therapy. On cessation of CsA treatment, the mean serum creatinine concentration fell to the upper reference limit. The elevation of serum creatinine concentration was significantly higher in patients who either developed hypertension during Cyclosporin A therapy or who were previously known to be hypertensive. Patients with nephrotoxicity were significantly older than those in whom serum creatinine concentration remained within the reference range. Lithium clearance studies showed evidence of proximal renal tubular dysfunction which was partially reversible on dose reduction or withdrawal.","tokens":[{"text":"Thirteen","start":0,"end":8,"id":0,"ws":true},{"text":"patients","start":8,"end":16,"id":1,"ws":true},{"text":"with","start":17,"end":21,"id":2,"ws":true},{"text":"chronic","start":22,"end":29,"id":3,"ws":true},{"text":"intraocular","start":30,"end":41,"id":4,"ws":true},{"text":"inflammation","start":42,"end":54,"id":5,"ws":true},{"text":"which","start":55,"end":60,"id":6,"ws":true},{"text":"had","start":61,"end":64,"id":7,"ws":true},{"text":"not","start":65,"end":68,"id":8,"ws":true},{"text":"been","start":69,"end":73,"id":9,"ws":true},{"text":"adequately","start":74,"end":84,"id":10,"ws":true},{"text":"controlled","start":85,"end":95,"id":11,"ws":true},{"text":"with","start":96,"end":100,"id":12,"ws":true},{"text":"oral","start":101,"end":105,"id":13,"ws":true},{"text":"prednisolone","start":106,"end":118,"id":14,"ws":true},{"text":"entered","start":119,"end":126,"id":15,"ws":true},{"text":"into","start":127,"end":131,"id":16,"ws":true},{"text":"an","start":132,"end":134,"id":17,"ws":true},{"text":"open","start":135,"end":139,"id":18,"ws":true},{"text":"study","start":140,"end":145,"id":19,"ws":true},{"text":"of","start":146,"end":148,"id":20,"ws":true},{"text":"low-dose","start":149,"end":157,"id":21,"ws":true},{"text":"Cyclosporin","start":158,"end":169,"id":22,"ws":true},{"text":"A","start":170,"end":171,"id":23,"ws":true},{"text":"(","start":172,"end":173,"id":24,"ws":true},{"text":"mean","start":174,"end":178,"id":25,"ws":true},{"text":"4.1","start":179,"end":182,"id":26,"ws":true},{"text":"mg/kg/day","start":183,"end":192,"id":27,"ws":true},{"text":")","start":193,"end":194,"id":28,"ws":true},{"text":"combined","start":195,"end":203,"id":29,"ws":true},{"text":"when","start":204,"end":208,"id":30,"ws":true},{"text":"required","start":209,"end":217,"id":31,"ws":true},{"text":"with","start":218,"end":222,"id":32,"ws":true},{"text":"oral","start":223,"end":227,"id":33,"ws":true},{"text":"prednisolone","start":228,"end":240,"id":34,"ws":true},{"text":"(","start":241,"end":242,"id":35,"ws":true},{"text":"15","start":243,"end":245,"id":36,"ws":true},{"text":"mg","start":246,"end":248,"id":37,"ws":true},{"text":"prednisolone","start":249,"end":261,"id":38,"ws":true},{"text":"per","start":262,"end":265,"id":39,"ws":true},{"text":"day","start":266,"end":269,"id":40,"ws":true},{"text":"or","start":270,"end":272,"id":41,"ws":true},{"text":"less","start":273,"end":277,"id":42,"ws":true},{"text":")","start":278,"end":279,"id":43,"ws":true},{"text":".","start":280,"end":281,"id":44,"ws":false}],"spans":[{"start":106,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},{"start":158,"end":169,"token_start":22,"token_end":22,"label":"DRUG"},{"start":228,"end":240,"token_start":34,"token_end":34,"label":"DRUG"},{"start":249,"end":261,"token_start":38,"token_end":38,"label":"DRUG"}],"_input_hash":-1159723586,"_task_hash":1910368263,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":22,"child":34,"head_span":{"start":158,"end":169,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":228,"end":240,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T1"],"answer":"accept"}
{"text":"A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer .","paragraph":"<h3><u>A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>Ib/II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HER3-targeting</i></b> <b style='color:MediumOrchid;'><i>lumretuzumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study investigated the safety and clinical activity of <b style='color:Tomato;'><i>lumretuzumab</i></b>, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC). HER3 ligand heregulin and HER3 protein expression were evaluated as potential biomarkers of clinical activity.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"phase","start":1,"end":6,"id":1,"ws":true},{"text":"Ib/II","start":7,"end":12,"id":2,"ws":true},{"text":"study","start":13,"end":18,"id":3,"ws":true},{"text":"of","start":19,"end":21,"id":4,"ws":true},{"text":"HER3-targeting","start":22,"end":36,"id":5,"ws":true},{"text":"lumretuzumab","start":37,"end":49,"id":6,"ws":true},{"text":"in","start":50,"end":52,"id":7,"ws":true},{"text":"combination","start":53,"end":64,"id":8,"ws":true},{"text":"with","start":65,"end":69,"id":9,"ws":true},{"text":"carboplatin","start":70,"end":81,"id":10,"ws":true},{"text":"and","start":82,"end":85,"id":11,"ws":true},{"text":"paclitaxel","start":86,"end":96,"id":12,"ws":true},{"text":"as","start":97,"end":99,"id":13,"ws":true},{"text":"first-line","start":100,"end":110,"id":14,"ws":true},{"text":"treatment","start":111,"end":120,"id":15,"ws":true},{"text":"in","start":121,"end":123,"id":16,"ws":true},{"text":"patients","start":124,"end":132,"id":17,"ws":true},{"text":"with","start":133,"end":137,"id":18,"ws":true},{"text":"advanced","start":138,"end":146,"id":19,"ws":true},{"text":"or","start":147,"end":149,"id":20,"ws":true},{"text":"metastatic","start":150,"end":160,"id":21,"ws":true},{"text":"squamous","start":161,"end":169,"id":22,"ws":true},{"text":"non-small","start":170,"end":179,"id":23,"ws":true},{"text":"cell","start":180,"end":184,"id":24,"ws":true},{"text":"lung","start":185,"end":189,"id":25,"ws":true},{"text":"cancer","start":190,"end":196,"id":26,"ws":true},{"text":".","start":197,"end":198,"id":27,"ws":false}],"spans":[{"start":37,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":81,"token_start":10,"token_end":10,"label":"DRUG"},{"start":86,"end":96,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":1118655691,"_task_hash":242717973,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":6,"child":10,"head_span":{"start":37,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":12,"head_span":{"start":70,"end":81,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":86,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB11","COMB1T0","COMB21","COMB2T0"],"answer":"accept"}
{"text":"A multicenter , prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component .","paragraph":"<h3><u>A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>axitinib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>predominant</i></b> <b style='color:DodgerBlue;'><i>sarcomatoid</i></b> <b style='color:DodgerBlue;'><i>component</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Introduction We conducted a multicenter, phase 2 trial using <b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> (GX) in patients with recurrent or metastatic sarcomatoid renal cell carcinoma (SRCC) to evaluate its efficacy and safety. Methods Patients with advanced RCC and a sarcomatoid component of \u226525% on resected kidney or exclusive sarcomatoid carcinoma on needle biopsy were included. Patients received <b style='color:Tomato;'><i>gemcitabine</i></b> 1000\u00a0mg/m","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"multicenter","start":1,"end":12,"id":1,"ws":true},{"text":",","start":13,"end":14,"id":2,"ws":true},{"text":"prospective","start":15,"end":26,"id":3,"ws":true},{"text":"phase","start":27,"end":32,"id":4,"ws":true},{"text":"II","start":33,"end":35,"id":5,"ws":true},{"text":"trial","start":36,"end":41,"id":6,"ws":true},{"text":"of","start":42,"end":44,"id":7,"ws":true},{"text":"gemcitabine","start":45,"end":56,"id":8,"ws":true},{"text":"plus","start":57,"end":61,"id":9,"ws":true},{"text":"axitinib","start":62,"end":70,"id":10,"ws":true},{"text":"in","start":71,"end":73,"id":11,"ws":true},{"text":"patients","start":74,"end":82,"id":12,"ws":true},{"text":"with","start":83,"end":87,"id":13,"ws":true},{"text":"renal","start":88,"end":93,"id":14,"ws":true},{"text":"cell","start":94,"end":98,"id":15,"ws":true},{"text":"carcinoma","start":99,"end":108,"id":16,"ws":true},{"text":"with","start":109,"end":113,"id":17,"ws":true},{"text":"a","start":114,"end":115,"id":18,"ws":true},{"text":"predominant","start":116,"end":127,"id":19,"ws":true},{"text":"sarcomatoid","start":128,"end":139,"id":20,"ws":true},{"text":"component","start":140,"end":149,"id":21,"ws":true},{"text":".","start":150,"end":151,"id":22,"ws":false}],"spans":[{"start":45,"end":56,"token_start":8,"token_end":8,"label":"DRUG"},{"start":62,"end":70,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-1960897245,"_task_hash":-418670972,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":45,"end":56,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":62,"end":70,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB11","COMB1T0"],"answer":"accept"}
{"text":"Prior to exposure to 75 % RH , the lactose blend was found to give the highest FPF of salbutamol ( 30 % by LD and 37 % by MSLI ) , followed by the sorbitol blend ( 17 % by LD and 29 % by MSLI ) , then by the dextrose blend ( 15 % by LD and 25 % by MSLI ) and finally by the maltose blend ( 13 % by LD and 13 % by MSLI ) .","paragraph":"<h3><u>Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.</u></h3>This paper presents the findings of two related studies. The aim of the first was to study any changes in the aerodynamic properties of <b style='color:Tomato;'><i>salbutamol</i></b> base powder formulations when different sugars were used as the carriers, after storage at an elevated humidity (75% RH), and whether any such changes (if any) were related to the physical properties of the carriers. The aim of the second was to investigate whether \"ageing\", i.e. storage of the carrier, drug and blends under desiccation for more than 2 years, affected the aerodynamic properties of <b style='color:Tomato;'><i>salbutamol</i></b> sulphate powder formulations. Different formulations were prepared, each containing 1.5% (w/w) micronised <b style='color:Tomato;'><i>salbutamol</i></b> base or sulphate blended with the sieved fraction (63-90 microm) of one of the following sugars: alpha <b style='color:Tomato;'><i>lactose</i></b> monohydrate, sorbitol, <b style='color:Tomato;'><i>maltose</i></b> and dextrose. The <b style='color:Tomato;'><i>salbutamol</i></b> base blends were then stored unprotected at 75% RH (ambient temperature) and <b style='color:Tomato;'><i>salbutamol</i></b> fine particle fractions (FPFs) were measured by laser diffraction (LD) (% < 5.2 microm) and a multistage liquid impinger (MSLI) (% < 5.3 microm), following aerosolisation at 100 l min(-1) from a model glass inhaler, after storage of each formulation at the elevated conditions for 0, 1 and 6 days. Particle morphology and equilibrium moisture content (EMC) of each formulation prior to and after storage were also evaluated. However, the <b style='color:Tomato;'><i>salbutamol</i></b> sulphate blends containing either \"fresh\" or \"aged\" components were only characterized using LD at 60 l min(-1). <b style='color:DodgerBlue;'><i>Prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exposure</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>RH</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>lactose</i></b> <b style='color:DodgerBlue;'><i>blend</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>give</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>highest</i></b> <b style='color:DodgerBlue;'><i>FPF</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>salbutamol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>37</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>MSLI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>sorbitol</i></b> <b style='color:DodgerBlue;'><i>blend</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>17</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>29</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>MSLI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dextrose</i></b> <b style='color:DodgerBlue;'><i>blend</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>MSLI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>finally</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>maltose</i></b> <b style='color:DodgerBlue;'><i>blend</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>13</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>LD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>13</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>MSLI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Exposure to 75% RH for 6 days resulted in a small reduction of <b style='color:Tomato;'><i>salbutamol</i></b> FPF from the <b style='color:Tomato;'><i>lactose</i></b> blend but drastic diminution of <b style='color:Tomato;'><i>salbutamol</i></b> FPFs from other blends. After exposure to the high RH, the <b style='color:Tomato;'><i>lactose</i></b> blend adsorbed ca. 0.4% whilst each of the other sugars took up larger quantities of water (15-40%) and underwent a marked change in the surface texture of the particles. \"Ageing\" of the carriers and/or formulations did not seem to alter the aerodynamic properties of the drug. \"Ageing\" of micronised <b style='color:Tomato;'><i>salbutamol</i></b> sulphate prior to blending, however, was found to improve the FPF of drug. LD was capable of detecting subtle differences between the various formulations and generated FPF results that correlated with those measured by MSLI.","tokens":[{"text":"Prior","start":0,"end":5,"id":0,"ws":true},{"text":"to","start":5,"end":7,"id":1,"ws":true},{"text":"exposure","start":8,"end":16,"id":2,"ws":true},{"text":"to","start":17,"end":19,"id":3,"ws":true},{"text":"75","start":20,"end":22,"id":4,"ws":true},{"text":"%","start":23,"end":24,"id":5,"ws":true},{"text":"RH","start":25,"end":27,"id":6,"ws":true},{"text":",","start":28,"end":29,"id":7,"ws":true},{"text":"the","start":30,"end":33,"id":8,"ws":true},{"text":"lactose","start":34,"end":41,"id":9,"ws":true},{"text":"blend","start":42,"end":47,"id":10,"ws":true},{"text":"was","start":48,"end":51,"id":11,"ws":true},{"text":"found","start":52,"end":57,"id":12,"ws":true},{"text":"to","start":58,"end":60,"id":13,"ws":true},{"text":"give","start":61,"end":65,"id":14,"ws":true},{"text":"the","start":66,"end":69,"id":15,"ws":true},{"text":"highest","start":70,"end":77,"id":16,"ws":true},{"text":"FPF","start":78,"end":81,"id":17,"ws":true},{"text":"of","start":82,"end":84,"id":18,"ws":true},{"text":"salbutamol","start":85,"end":95,"id":19,"ws":true},{"text":"(","start":96,"end":97,"id":20,"ws":true},{"text":"30","start":98,"end":100,"id":21,"ws":true},{"text":"%","start":101,"end":102,"id":22,"ws":true},{"text":"by","start":103,"end":105,"id":23,"ws":true},{"text":"LD","start":106,"end":108,"id":24,"ws":true},{"text":"and","start":109,"end":112,"id":25,"ws":true},{"text":"37","start":113,"end":115,"id":26,"ws":true},{"text":"%","start":116,"end":117,"id":27,"ws":true},{"text":"by","start":118,"end":120,"id":28,"ws":true},{"text":"MSLI","start":121,"end":125,"id":29,"ws":true},{"text":")","start":126,"end":127,"id":30,"ws":true},{"text":",","start":128,"end":129,"id":31,"ws":true},{"text":"followed","start":130,"end":138,"id":32,"ws":true},{"text":"by","start":139,"end":141,"id":33,"ws":true},{"text":"the","start":142,"end":145,"id":34,"ws":true},{"text":"sorbitol","start":146,"end":154,"id":35,"ws":true},{"text":"blend","start":155,"end":160,"id":36,"ws":true},{"text":"(","start":161,"end":162,"id":37,"ws":true},{"text":"17","start":163,"end":165,"id":38,"ws":true},{"text":"%","start":166,"end":167,"id":39,"ws":true},{"text":"by","start":168,"end":170,"id":40,"ws":true},{"text":"LD","start":171,"end":173,"id":41,"ws":true},{"text":"and","start":174,"end":177,"id":42,"ws":true},{"text":"29","start":178,"end":180,"id":43,"ws":true},{"text":"%","start":181,"end":182,"id":44,"ws":true},{"text":"by","start":183,"end":185,"id":45,"ws":true},{"text":"MSLI","start":186,"end":190,"id":46,"ws":true},{"text":")","start":191,"end":192,"id":47,"ws":true},{"text":",","start":193,"end":194,"id":48,"ws":true},{"text":"then","start":195,"end":199,"id":49,"ws":true},{"text":"by","start":200,"end":202,"id":50,"ws":true},{"text":"the","start":203,"end":206,"id":51,"ws":true},{"text":"dextrose","start":207,"end":215,"id":52,"ws":true},{"text":"blend","start":216,"end":221,"id":53,"ws":true},{"text":"(","start":222,"end":223,"id":54,"ws":true},{"text":"15","start":224,"end":226,"id":55,"ws":true},{"text":"%","start":227,"end":228,"id":56,"ws":true},{"text":"by","start":229,"end":231,"id":57,"ws":true},{"text":"LD","start":232,"end":234,"id":58,"ws":true},{"text":"and","start":235,"end":238,"id":59,"ws":true},{"text":"25","start":239,"end":241,"id":60,"ws":true},{"text":"%","start":242,"end":243,"id":61,"ws":true},{"text":"by","start":244,"end":246,"id":62,"ws":true},{"text":"MSLI","start":247,"end":251,"id":63,"ws":true},{"text":")","start":252,"end":253,"id":64,"ws":true},{"text":"and","start":254,"end":257,"id":65,"ws":true},{"text":"finally","start":258,"end":265,"id":66,"ws":true},{"text":"by","start":266,"end":268,"id":67,"ws":true},{"text":"the","start":269,"end":272,"id":68,"ws":true},{"text":"maltose","start":273,"end":280,"id":69,"ws":true},{"text":"blend","start":281,"end":286,"id":70,"ws":true},{"text":"(","start":287,"end":288,"id":71,"ws":true},{"text":"13","start":289,"end":291,"id":72,"ws":true},{"text":"%","start":292,"end":293,"id":73,"ws":true},{"text":"by","start":294,"end":296,"id":74,"ws":true},{"text":"LD","start":297,"end":299,"id":75,"ws":true},{"text":"and","start":300,"end":303,"id":76,"ws":true},{"text":"13","start":304,"end":306,"id":77,"ws":true},{"text":"%","start":307,"end":308,"id":78,"ws":true},{"text":"by","start":309,"end":311,"id":79,"ws":true},{"text":"MSLI","start":312,"end":316,"id":80,"ws":true},{"text":")","start":317,"end":318,"id":81,"ws":true},{"text":".","start":319,"end":320,"id":82,"ws":false}],"spans":[{"start":34,"end":41,"token_start":9,"token_end":9,"label":"DRUG"},{"start":85,"end":95,"token_start":19,"token_end":19,"label":"DRUG"},{"start":273,"end":280,"token_start":69,"token_end":69,"label":"DRUG"}],"_input_hash":-230304351,"_task_hash":-702558075,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A recent phase I/II study examined the combination of Epidermal Growth Factor Receptor (EGFR)-TKI erlotinib and bevacizumab in patients with non-squamous stage IIIB/IV NSCLC .","paragraph":"<h3><u>New antiangiogenetic agents and non-small cell lung cancer.</u></h3>New blood vessel formation, known as angiogenesis is a fundamental event in the process of tumor growth and metastatic dissemination. Due to its central role in tumor angiogenesis, the vascular endothelial growth factor (VEGF) and its receptor have been a major focus of basic research and drug development in the field of oncology, including the treatment of non-small cell lung cancer (NSCLC). Approaches targeting VEGF include monoclonal antibodies and vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). Bevacizumab (Avastin) is an anti-VEGF recombinant humanized monoclonal antibody. A very recent randomized phase III trial demonstrated a statistically significant advantage in median survival favouring the combination of <b style='color:Tomato;'><i>bevacizumab</i></b> plus chemotherapy versus chemotherapy alone in the treatment of advanced non-squamous NSCLC. This study represents the first evidence of superior efficacy of targeted therapy combined with chemotherapy over chemotherapy alone in the treatment of NSCLC. ZD6474 is an orally bioavailable inhibitor of VEGFR-2 tyrosine kinase. First evidences of antitumor activity and its excellent toxicity profile make it a promising targeted agent for the treatment of NSCLC. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>recent</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Epidermal</i></b> <b style='color:DodgerBlue;'><i>Growth</i></b> <b style='color:DodgerBlue;'><i>Factor</i></b> <b style='color:DodgerBlue;'><i>Receptor</i></b> <b style='color:DodgerBlue;'><i>(EGFR)-TKI</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>non-squamous</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIB/IV</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Data on antitumor activity of this combination have to be considered very promising. Clinical trials of multiple targeted therapy may represent the second generation studies in the treatment of NSCLC.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"recent","start":1,"end":7,"id":1,"ws":true},{"text":"phase","start":8,"end":13,"id":2,"ws":true},{"text":"I/II","start":14,"end":18,"id":3,"ws":true},{"text":"study","start":19,"end":24,"id":4,"ws":true},{"text":"examined","start":25,"end":33,"id":5,"ws":true},{"text":"the","start":34,"end":37,"id":6,"ws":true},{"text":"combination","start":38,"end":49,"id":7,"ws":true},{"text":"of","start":50,"end":52,"id":8,"ws":true},{"text":"Epidermal","start":53,"end":62,"id":9,"ws":true},{"text":"Growth","start":63,"end":69,"id":10,"ws":true},{"text":"Factor","start":70,"end":76,"id":11,"ws":true},{"text":"Receptor","start":77,"end":85,"id":12,"ws":true},{"text":"(EGFR)-TKI","start":86,"end":96,"id":13,"ws":true},{"text":"erlotinib","start":97,"end":106,"id":14,"ws":true},{"text":"and","start":107,"end":110,"id":15,"ws":true},{"text":"bevacizumab","start":111,"end":122,"id":16,"ws":true},{"text":"in","start":123,"end":125,"id":17,"ws":true},{"text":"patients","start":126,"end":134,"id":18,"ws":true},{"text":"with","start":135,"end":139,"id":19,"ws":true},{"text":"non-squamous","start":140,"end":152,"id":20,"ws":true},{"text":"stage","start":153,"end":158,"id":21,"ws":true},{"text":"IIIB/IV","start":159,"end":166,"id":22,"ws":true},{"text":"NSCLC","start":167,"end":172,"id":23,"ws":true},{"text":".","start":173,"end":174,"id":24,"ws":false}],"spans":[{"start":97,"end":106,"token_start":14,"token_end":14,"label":"DRUG"},{"start":111,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":257730854,"_task_hash":-1071651005,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":13,"child":16,"head_span":{"start":86,"end":96,"token_start":13,"token_end":13,"label":null},"child_span":{"start":111,"end":122,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer , and the mechanism of vemurafenib resistance remains unclear .","paragraph":"<h3><u>Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.</u></h3> <b style='color:MediumOrchid;'><i>Vemurafenib</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>B-Raf</i></b> <b style='color:DodgerBlue;'><i>V600E</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>exerts</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>inhibitory</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>colon</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mechanism</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vemurafenib</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>remains</i></b> <b style='color:DodgerBlue;'><i>unclear</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, bioinformatics analysis of gene profiles in cancer cells treated with <b style='color:Tomato;'><i>vemurafenib</i></b> or its analog revealed that cell cycle progression is significantly affected by <b style='color:Tomato;'><i>vemurafenib</i></b>. We found that CDK1 is stably activated in the <b style='color:Tomato;'><i>vemurafenib</i></b>-resistant (VR) colon cancer sublines that we established, indicating that CDK1 activation is responsible for <b style='color:Tomato;'><i>vemurafenib</i></b> resistance. As the KCTD12-CDK1 interaction is necessary for CDK1 activation, we screened an FDA-approved drug library consisting of 616 compounds and identified that <b style='color:Tomato;'><i>adefovir</i></b> dipivoxil (AD), a nucleoside analog for treatment of HBV infections, disrupts the CDK1-KCTD12 interaction and induces G2 phase arrest in the cell cycle. Functional assays demonstrated that AD significantly inhibited colon cancer cell proliferation and tumorigenesis both in vitro and in vivo with no observed side effects. Furthermore, AD sensitized <b style='color:Tomato;'><i>vemurafenib</i></b>-resistant colon cancer cells and tumor xenografts to <b style='color:Tomato;'><i>vemurafenib</i></b>. This study reveals that CDK1 activation induces <b style='color:Tomato;'><i>vemurafenib</i></b> resistance and that AD is a promising therapeutic strategy for colon cancer both as a single agent and in combination with <b style='color:Tomato;'><i>vemurafenib</i></b>.","tokens":[{"text":"Vemurafenib","start":0,"end":11,"id":0,"ws":true},{"text":"is","start":11,"end":13,"id":1,"ws":true},{"text":"a","start":14,"end":15,"id":2,"ws":true},{"text":"B-Raf","start":16,"end":21,"id":3,"ws":true},{"text":"V600E","start":22,"end":27,"id":4,"ws":true},{"text":"inhibitor","start":28,"end":37,"id":5,"ws":true},{"text":"that","start":38,"end":42,"id":6,"ws":true},{"text":"exerts","start":43,"end":49,"id":7,"ws":true},{"text":"significant","start":50,"end":61,"id":8,"ws":true},{"text":"inhibitory","start":62,"end":72,"id":9,"ws":true},{"text":"effects","start":73,"end":80,"id":10,"ws":true},{"text":"in","start":81,"end":83,"id":11,"ws":true},{"text":"melanoma","start":84,"end":92,"id":12,"ws":true},{"text":"but","start":93,"end":96,"id":13,"ws":true},{"text":"not","start":97,"end":100,"id":14,"ws":true},{"text":"in","start":101,"end":103,"id":15,"ws":true},{"text":"colon","start":104,"end":109,"id":16,"ws":true},{"text":"cancer","start":110,"end":116,"id":17,"ws":true},{"text":",","start":117,"end":118,"id":18,"ws":true},{"text":"and","start":119,"end":122,"id":19,"ws":true},{"text":"the","start":123,"end":126,"id":20,"ws":true},{"text":"mechanism","start":127,"end":136,"id":21,"ws":true},{"text":"of","start":137,"end":139,"id":22,"ws":true},{"text":"vemurafenib","start":140,"end":151,"id":23,"ws":true},{"text":"resistance","start":152,"end":162,"id":24,"ws":true},{"text":"remains","start":163,"end":170,"id":25,"ws":true},{"text":"unclear","start":171,"end":178,"id":26,"ws":true},{"text":".","start":179,"end":180,"id":27,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":140,"end":151,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":-233560528,"_task_hash":1529741507,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Metoprolol showed a linear dose-symptom relationship , whereas propranolol and sotalol seemed to have a threshold dose beyond which symptoms aggravated .","paragraph":"<h3><u>Clinical toxicology of beta-blocker overdose in adults.</u></h3>Beta-blocker overdose is potentially harmful due to the strong blood pressure-lowering and heart rate-lowering effects. However, conflicting data exist as to their differential toxicity, single-substance exposures and the effect of co-exposure with additional antihypertensive medication. For this, a 10-year retrospective, explorative analysis of the Mainz Poison Center/Germany database with regard to circumstances of beta-blocker exposure, doses, symptoms and treatment was carried out. Analyses were restricted to adult patients with single-substance exposures and co-exposures with one additional antihypertensive substance. Written follow-up information was obtained in half the cases. A total of 2967 cases were analysed, of which 697 were single-substance exposures. Metoprolol was most frequently reported followed by <b style='color:Tomato;'><i>bisoprolol</i></b>, <b style='color:Tomato;'><i>atenolol</i></b>, <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>sotalol</i></b>. <b style='color:MediumOrchid;'><i>Metoprolol</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>linear</i></b> <b style='color:DodgerBlue;'><i>dose-symptom</i></b> <b style='color:DodgerBlue;'><i>relationship</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sotalol</i></b> <b style='color:DodgerBlue;'><i>seemed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>threshold</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>beyond</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>symptoms</i></b> <b style='color:DodgerBlue;'><i>aggravated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Symptoms did not differ substantially, except for more seizures being reported with <b style='color:Tomato;'><i>propranolol</i></b>, and more CNS depression/vomiting with <b style='color:Tomato;'><i>sotalol</i></b>. Activated charcoal was used in 38%, gastric lavage in 11%, temporary pacemaker in 3%, glucagon in 1%, intubation for respiratory insufficiency and cardiopulmonary resuscitation in 1% and 0.5%. All patients recovered. In 174 co-exposure cases, the distribution of poisoning severity and rate of worsening of symptoms was comparable with single-substance exposures except one patient deceased after <b style='color:Tomato;'><i>bisoprolol</i></b> and <b style='color:Tomato;'><i>verapamil</i></b> co-exposure. In adults with beta-blocker overdose, no significant differences in poisoning severity among beta-blockers were detected, and no fatalities were observed with single-substance exposures. Co-exposures with other antihypertensives, sedatives or alcohol should be carefully attended to as fatalities might occur.","tokens":[{"text":"Metoprolol","start":0,"end":10,"id":0,"ws":true},{"text":"showed","start":10,"end":16,"id":1,"ws":true},{"text":"a","start":17,"end":18,"id":2,"ws":true},{"text":"linear","start":19,"end":25,"id":3,"ws":true},{"text":"dose-symptom","start":26,"end":38,"id":4,"ws":true},{"text":"relationship","start":39,"end":51,"id":5,"ws":true},{"text":",","start":52,"end":53,"id":6,"ws":true},{"text":"whereas","start":54,"end":61,"id":7,"ws":true},{"text":"propranolol","start":62,"end":73,"id":8,"ws":true},{"text":"and","start":74,"end":77,"id":9,"ws":true},{"text":"sotalol","start":78,"end":85,"id":10,"ws":true},{"text":"seemed","start":86,"end":92,"id":11,"ws":true},{"text":"to","start":93,"end":95,"id":12,"ws":true},{"text":"have","start":96,"end":100,"id":13,"ws":true},{"text":"a","start":101,"end":102,"id":14,"ws":true},{"text":"threshold","start":103,"end":112,"id":15,"ws":true},{"text":"dose","start":113,"end":117,"id":16,"ws":true},{"text":"beyond","start":118,"end":124,"id":17,"ws":true},{"text":"which","start":125,"end":130,"id":18,"ws":true},{"text":"symptoms","start":131,"end":139,"id":19,"ws":true},{"text":"aggravated","start":140,"end":150,"id":20,"ws":true},{"text":".","start":151,"end":152,"id":21,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":62,"end":73,"token_start":8,"token_end":8,"label":"DRUG"},{"start":78,"end":85,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":-81466809,"_task_hash":1012522008,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Specifically , azathioprine , cyclophosphamide , methotrexate , cyclosporine , mycophenolate mofetil and dapsone are now widely used in PV .","paragraph":"<h3><u>Pemphigus vulgaris: approach to treatment.</u></h3>The therapeutic management of pemphigus vulgaris (PV) is centered around immunosuppression, which can be generalized, as in the use of corticosteroids or steroid sparing agents, or specific, as in therapeutic blockage of autoantibody production, certain cytokines, or signaling pathways. Currently, the backbone of treatment for PV, particularly, first line therapy, remains systemic corticosteroids. Although very effective, the significant side effects of long-term corticosteroid usage are well documented. Adjunctive therapies aim to eliminate, or at least decrease, the necessary dose of corticosteroids. <b style='color:DodgerBlue;'><i>Specifically</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>azathioprine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dapsone</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>PV</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intravenous immunoglobulin (IVIG), plasmapheresis, immunoadsorption, and most recently, <b style='color:Tomato;'><i>rituximab</i></b>, are other members of the therapeutic armamentarium. However, despite the widening range of treatment options in PV, well-controlled clinical trials and consensus guidelines are lacking. ","tokens":[{"text":"Specifically","start":0,"end":12,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"azathioprine","start":14,"end":26,"id":2,"ws":true},{"text":",","start":27,"end":28,"id":3,"ws":true},{"text":"cyclophosphamide","start":29,"end":45,"id":4,"ws":true},{"text":",","start":46,"end":47,"id":5,"ws":true},{"text":"methotrexate","start":48,"end":60,"id":6,"ws":true},{"text":",","start":61,"end":62,"id":7,"ws":true},{"text":"cyclosporine","start":63,"end":75,"id":8,"ws":true},{"text":",","start":76,"end":77,"id":9,"ws":true},{"text":"mycophenolate","start":78,"end":91,"id":10,"ws":true},{"text":"mofetil","start":92,"end":99,"id":11,"ws":true},{"text":"and","start":100,"end":103,"id":12,"ws":true},{"text":"dapsone","start":104,"end":111,"id":13,"ws":true},{"text":"are","start":112,"end":115,"id":14,"ws":true},{"text":"now","start":116,"end":119,"id":15,"ws":true},{"text":"widely","start":120,"end":126,"id":16,"ws":true},{"text":"used","start":127,"end":131,"id":17,"ws":true},{"text":"in","start":132,"end":134,"id":18,"ws":true},{"text":"PV","start":135,"end":137,"id":19,"ws":true},{"text":".","start":138,"end":139,"id":20,"ws":false}],"spans":[{"start":14,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":45,"token_start":4,"token_end":4,"label":"DRUG"},{"start":48,"end":60,"token_start":6,"token_end":6,"label":"DRUG"},{"start":63,"end":75,"token_start":8,"token_end":8,"label":"DRUG"},{"start":78,"end":91,"token_start":10,"token_end":10,"label":"DRUG"}],"_input_hash":895633444,"_task_hash":1485060663,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A comparison of adriamycin versus vincristine and adriamycin , and cyclophosphamide versus vincristine , actinomycin-D , and cyclophosphamide for advanced sarcoma .","paragraph":"<h3><u>A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma.</u></h3> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>sarcoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This randomized study, conducted by the Eastern cooperative Oncology Group, compared Adriamycin (<b style='color:Tomato;'><i>doxorubicin</i></b>) (70 mg/m2) versus <b style='color:Tomato;'><i>vincristine</i></b> (1.4 mg/m2) and Adriamycin (50 mg/m2); and <b style='color:Tomato;'><i>cyclophosphamide</i></b> (750 mg/m2) versus <b style='color:Tomato;'><i>vincristine</i></b> (1.4 mg/m2), actinomycin-D (0.4 mg/m2), and <b style='color:Tomato;'><i>cyclophosphamide</i></b> (750 mg/m2) for treatment of metastatic mesenchymal malignancies. The respective response rate seen in 200 evaluable patients to the treatments were, 27, 19, and 11%. The response rate to Adriamycin was significant better than the response to <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> (P = 0.03, two-sided). The respective median survivals on the three treatments were 37, 34, and 41 weeks and were not significantly different. Moderate or severe vomiting occurred in 60% of patients receiving <b style='color:Tomato;'><i>vincristine</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b>-adriamycin, a greater frequency than in Adriamycin alone (P = .09 two-sided) Severe or life-threatening hematologic toxicity (leukocytes less than 2000, platelets less than 50,000) occurred in 30% of patients receiving the Adriamycin combination, a markedly increased frequency when compared to the other two regimens (P equals 0.07, P = 0.02, two-sided). This trial establishes that Adriamycin has a better response rate than the combination of <b style='color:Tomato;'><i>vincristine</i></b>-actinomycin-D-<b style='color:Tomato;'><i>cyclophosphamide</i></b> in advanced sarcomas. The combination of <b style='color:Tomato;'><i>vincristine</i></b>, Adriamycin, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> increased toxicity and did not add to the therapeutic effect achieved with Adriamycin alone.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"comparison","start":1,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"adriamycin","start":15,"end":25,"id":3,"ws":true},{"text":"versus","start":26,"end":32,"id":4,"ws":true},{"text":"vincristine","start":33,"end":44,"id":5,"ws":true},{"text":"and","start":45,"end":48,"id":6,"ws":true},{"text":"adriamycin","start":49,"end":59,"id":7,"ws":true},{"text":",","start":60,"end":61,"id":8,"ws":true},{"text":"and","start":62,"end":65,"id":9,"ws":true},{"text":"cyclophosphamide","start":66,"end":82,"id":10,"ws":true},{"text":"versus","start":83,"end":89,"id":11,"ws":true},{"text":"vincristine","start":90,"end":101,"id":12,"ws":true},{"text":",","start":102,"end":103,"id":13,"ws":true},{"text":"actinomycin-D","start":104,"end":117,"id":14,"ws":true},{"text":",","start":118,"end":119,"id":15,"ws":true},{"text":"and","start":120,"end":123,"id":16,"ws":true},{"text":"cyclophosphamide","start":124,"end":140,"id":17,"ws":true},{"text":"for","start":141,"end":144,"id":18,"ws":true},{"text":"advanced","start":145,"end":153,"id":19,"ws":true},{"text":"sarcoma","start":154,"end":161,"id":20,"ws":true},{"text":".","start":162,"end":163,"id":21,"ws":false}],"spans":[{"start":33,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},{"start":66,"end":82,"token_start":10,"token_end":10,"label":"DRUG"},{"start":90,"end":101,"token_start":12,"token_end":12,"label":"DRUG"},{"start":124,"end":140,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":1818993875,"_task_hash":-1903179322,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":33,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":49,"end":59,"token_start":7,"token_end":7,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":7,"child":10,"head_span":{"start":49,"end":59,"token_start":7,"token_end":7,"label":null},"child_span":{"start":66,"end":82,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":12,"child":14,"head_span":{"start":90,"end":101,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":104,"end":117,"token_start":14,"token_end":14,"label":null},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB11","COMB1T0","COMB21","COMB2T0","COMB31","COMB3T0"],"answer":"accept"}
{"text":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation .","paragraph":"<h3><u>Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.</u></h3> <b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>mammalian</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>hepatocellular</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There is currently no consensus on the most suitable treatment for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter, retrospective, uncontrolled cohort study was designed to evaluate the safety and preliminary efficacy of the combined use of a mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitor and <b style='color:Tomato;'><i>sorafenib</i></b> in this setting. In 31 patients who suffered from HCC recurrence after liver transplantation, the immunosuppressive therapy was changed to mTOR inhibitors, and systemic treatment with <b style='color:Tomato;'><i>sorafenib</i></b> was initiated. This combination was maintained until symptomatic tumor progression, death, hepatic decompensation, or unacceptable toxicity occurred. Primary treatment efficacy was determined by overall survival and progression-free survival, and secondary efficacy was determined by the overall response rate. Toxicity parameters associated with the use of <b style='color:Tomato;'><i>sorafenib</i></b> and mTOR inhibitors were also analyzed. The overall response rate according to the Response Evaluation Criteria in Solid Tumors was 3.8% (1/26), and there was sustained stabilization of the disease in 13 additional cases (50.0%). The median overall survival was 19.3 months [95% confidence interval (CI) = 13.4-25.1 months], and the median time to progression was 6.77 months (95% CI = 2.3-11.1 months). Only 2 grade 3/4 cases of hyperglycemia and 1 case of grade 3/4 mucositis were reported, and they were possibly related to mTOR inhibitors. The most common severe adverse event probably related to <b style='color:Tomato;'><i>sorafenib</i></b> was diarrhea (12.9%). In conclusion, the coadministration of <b style='color:Tomato;'><i>sorafenib</i></b> and an mTOR inhibitor could be effective despite notable toxicity in patients with post-liver transplant HCC recurrence not suitable for radical therapy. The toxicity and efficacy need to be further evaluated in randomized controlled studies for this combination to be considered a valid option.","tokens":[{"text":"Efficacy","start":0,"end":8,"id":0,"ws":true},{"text":"and","start":8,"end":11,"id":1,"ws":true},{"text":"safety","start":12,"end":18,"id":2,"ws":true},{"text":"of","start":19,"end":21,"id":3,"ws":true},{"text":"sorafenib","start":22,"end":31,"id":4,"ws":true},{"text":"in","start":32,"end":34,"id":5,"ws":true},{"text":"combination","start":35,"end":46,"id":6,"ws":true},{"text":"with","start":47,"end":51,"id":7,"ws":true},{"text":"mammalian","start":52,"end":61,"id":8,"ws":true},{"text":"target","start":62,"end":68,"id":9,"ws":true},{"text":"of","start":69,"end":71,"id":10,"ws":true},{"text":"rapamycin","start":72,"end":81,"id":11,"ws":true},{"text":"inhibitors","start":82,"end":92,"id":12,"ws":true},{"text":"for","start":93,"end":96,"id":13,"ws":true},{"text":"recurrent","start":97,"end":106,"id":14,"ws":true},{"text":"hepatocellular","start":107,"end":121,"id":15,"ws":true},{"text":"carcinoma","start":122,"end":131,"id":16,"ws":true},{"text":"after","start":132,"end":137,"id":17,"ws":true},{"text":"liver","start":138,"end":143,"id":18,"ws":true},{"text":"transplantation","start":144,"end":159,"id":19,"ws":true},{"text":".","start":160,"end":161,"id":20,"ws":false}],"spans":[{"start":22,"end":31,"token_start":4,"token_end":4,"label":"DRUG"},{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":947530806,"_task_hash":1332641398,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":4,"child":11,"head_span":{"start":22,"end":31,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB11","COMB1T0"],"answer":"accept"}
{"text":"These groups were used to evaluate the effects of captopril administration alone , or following bradykinin B2 receptor blockade or nitric oxide synthase inhibition , on a number of haemodynamic parameters ( mean arterial pressure , cardiac index , vascular resistance and heart rate ) .","paragraph":"<h3><u>17Beta-oestradiol enhances the acute hypotensive effect of captopril in female ovariectomized spontaneously hypertensive rats.</u></h3>The objective of this study was to investigate whether the acute haemodynamic effects of angiotensin-converting enzyme inhibition with <b style='color:Tomato;'><i>captopril</i></b> could be enhanced by oestrogen administration, and then to evaluate the mechanisms involved in this enhancement. All experiments were performed in 18-week-old female spontaneously hypertensive rats arranged in three experimental groups: intact; ovariectomized (OVX); and ovariectomized plus treatment with 17beta-oestradiol (OVX + E2). <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>bradykinin</i></b> <b style='color:DodgerBlue;'><i>B2</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>blockade</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>nitric</i></b> <b style='color:DodgerBlue;'><i>oxide</i></b> <b style='color:DodgerBlue;'><i>synthase</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>haemodynamic</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>index</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>heart</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The drop in mean arterial pressure and vascular resistance index in response to <b style='color:Tomato;'><i>captopril</i></b> was more pronounced in intact and ovariectomized rats treated with 17beta-oestradiol than in ovariectomized animals. Blockade of <b style='color:Tomato;'><i>bradykinin</i></b> B2 receptors or inhibition of nitric oxide synthesis attenuated the synergy between 17beta-oestradiol and <b style='color:Tomato;'><i>captopril</i></b>. It is concluded that ovariectomy blunted the blood pressure and vascular resistance index drop observed in intact rats in response to <b style='color:Tomato;'><i>captopril</i></b>. Treatment with 17beta-oestradiol prevented the blunted response to <b style='color:Tomato;'><i>captopril</i></b> in ovariectomized rats. Kinins and nitric oxide may be involved in the mechanisms of 17beta-oestradiol potentiation of the haemodynamic effects of <b style='color:Tomato;'><i>captopril</i></b>.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"groups","start":5,"end":11,"id":1,"ws":true},{"text":"were","start":12,"end":16,"id":2,"ws":true},{"text":"used","start":17,"end":21,"id":3,"ws":true},{"text":"to","start":22,"end":24,"id":4,"ws":true},{"text":"evaluate","start":25,"end":33,"id":5,"ws":true},{"text":"the","start":34,"end":37,"id":6,"ws":true},{"text":"effects","start":38,"end":45,"id":7,"ws":true},{"text":"of","start":46,"end":48,"id":8,"ws":true},{"text":"captopril","start":49,"end":58,"id":9,"ws":true},{"text":"administration","start":59,"end":73,"id":10,"ws":true},{"text":"alone","start":74,"end":79,"id":11,"ws":true},{"text":",","start":80,"end":81,"id":12,"ws":true},{"text":"or","start":82,"end":84,"id":13,"ws":true},{"text":"following","start":85,"end":94,"id":14,"ws":true},{"text":"bradykinin","start":95,"end":105,"id":15,"ws":true},{"text":"B2","start":106,"end":108,"id":16,"ws":true},{"text":"receptor","start":109,"end":117,"id":17,"ws":true},{"text":"blockade","start":118,"end":126,"id":18,"ws":true},{"text":"or","start":127,"end":129,"id":19,"ws":true},{"text":"nitric","start":130,"end":136,"id":20,"ws":true},{"text":"oxide","start":137,"end":142,"id":21,"ws":true},{"text":"synthase","start":143,"end":151,"id":22,"ws":true},{"text":"inhibition","start":152,"end":162,"id":23,"ws":true},{"text":",","start":163,"end":164,"id":24,"ws":true},{"text":"on","start":165,"end":167,"id":25,"ws":true},{"text":"a","start":168,"end":169,"id":26,"ws":true},{"text":"number","start":170,"end":176,"id":27,"ws":true},{"text":"of","start":177,"end":179,"id":28,"ws":true},{"text":"haemodynamic","start":180,"end":192,"id":29,"ws":true},{"text":"parameters","start":193,"end":203,"id":30,"ws":true},{"text":"(","start":204,"end":205,"id":31,"ws":true},{"text":"mean","start":206,"end":210,"id":32,"ws":true},{"text":"arterial","start":211,"end":219,"id":33,"ws":true},{"text":"pressure","start":220,"end":228,"id":34,"ws":true},{"text":",","start":229,"end":230,"id":35,"ws":true},{"text":"cardiac","start":231,"end":238,"id":36,"ws":true},{"text":"index","start":239,"end":244,"id":37,"ws":true},{"text":",","start":245,"end":246,"id":38,"ws":true},{"text":"vascular","start":247,"end":255,"id":39,"ws":true},{"text":"resistance","start":256,"end":266,"id":40,"ws":true},{"text":"and","start":267,"end":270,"id":41,"ws":true},{"text":"heart","start":271,"end":276,"id":42,"ws":true},{"text":"rate","start":277,"end":281,"id":43,"ws":true},{"text":")","start":282,"end":283,"id":44,"ws":true},{"text":".","start":284,"end":285,"id":45,"ws":false}],"spans":[{"start":49,"end":58,"token_start":9,"token_end":9,"label":"DRUG"},{"start":95,"end":105,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":-976185228,"_task_hash":2040032053,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":9,"child":15,"head_span":{"start":49,"end":58,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":95,"end":105,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Patients were randomized to receive radiation and carboplatin ( RCT ) alone or RCT preceded by rapid infusion of amifostine ( 500 mg ) on days carboplatin was administered .","paragraph":"<h3><u>Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.</u></h3>In a randomized phase II trial in Germany, we investigated the clinical and economic impact of <b style='color:Tomato;'><i>amifostine</i></b> protection against the hematological and oral toxicities of <b style='color:Tomato;'><i>carboplatin</i></b> administered concurrently with standard fractions of radiotherapy. 28 patients with squamous cell carcinomas of the head and neck received adjunctive or primary radiotherapy (5 days per week with daily fractions of 2 Gy, up to a total dose of 60 Gy) in conjunction with <b style='color:Tomato;'><i>carboplatin</i></b> (70 mg/m2) on days 1-5 and days 21-26. All patients received radiation encompassing at least 75% of the major salivary glands. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>radiation</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>RCT</i></b> <b style='color:DodgerBlue;'><i>preceded</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>rapid</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amifostine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The 14 patients who received <b style='color:Tomato;'><i>amifostine</i></b>, in comparison to 14 patients in the control arm, had significantly fewer episodes of grade 3 or 4 thrombocytopenia (p = 0.001), mucositis (p = 0.001), and xerostomia (p = 0.001). The patients receiving <b style='color:Tomato;'><i>amifostine</i></b> accrued significantly lower supportive care costs for resources related to infection ($241 vs. $1,275, p < 0.01), red blood cell and platelet support ($286 vs. $1,276 p = 0.06) alimentation ($343 vs. $894, p = .01), and hospitalization ($286 vs. $2,429, p < 0.01). Overall, including the costs of <b style='color:Tomato;'><i>amifostine</i></b>, mean per patient supportive care costs were $4,401 for the <b style='color:Tomato;'><i>amifostine</i></b> group and $5,873 (p = .02) for the control group. Our results from a randomized phase II trial indicate that selective cytoprotection with <b style='color:Tomato;'><i>amifostine</i></b> potentially offers clinical and economic benefits in patients with advanced head and neck cancer receiving radiochemotherapy. Additional economic studies alongside randomized phase III trials and from other countries are needed.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"were","start":8,"end":12,"id":1,"ws":true},{"text":"randomized","start":13,"end":23,"id":2,"ws":true},{"text":"to","start":24,"end":26,"id":3,"ws":true},{"text":"receive","start":27,"end":34,"id":4,"ws":true},{"text":"radiation","start":35,"end":44,"id":5,"ws":true},{"text":"and","start":45,"end":48,"id":6,"ws":true},{"text":"carboplatin","start":49,"end":60,"id":7,"ws":true},{"text":"(","start":61,"end":62,"id":8,"ws":true},{"text":"RCT","start":63,"end":66,"id":9,"ws":true},{"text":")","start":67,"end":68,"id":10,"ws":true},{"text":"alone","start":69,"end":74,"id":11,"ws":true},{"text":"or","start":75,"end":77,"id":12,"ws":true},{"text":"RCT","start":78,"end":81,"id":13,"ws":true},{"text":"preceded","start":82,"end":90,"id":14,"ws":true},{"text":"by","start":91,"end":93,"id":15,"ws":true},{"text":"rapid","start":94,"end":99,"id":16,"ws":true},{"text":"infusion","start":100,"end":108,"id":17,"ws":true},{"text":"of","start":109,"end":111,"id":18,"ws":true},{"text":"amifostine","start":112,"end":122,"id":19,"ws":true},{"text":"(","start":123,"end":124,"id":20,"ws":true},{"text":"500","start":125,"end":128,"id":21,"ws":true},{"text":"mg","start":129,"end":131,"id":22,"ws":true},{"text":")","start":132,"end":133,"id":23,"ws":true},{"text":"on","start":134,"end":136,"id":24,"ws":true},{"text":"days","start":137,"end":141,"id":25,"ws":true},{"text":"carboplatin","start":142,"end":153,"id":26,"ws":true},{"text":"was","start":154,"end":157,"id":27,"ws":true},{"text":"administered","start":158,"end":170,"id":28,"ws":true},{"text":".","start":171,"end":172,"id":29,"ws":false}],"spans":[{"start":49,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":112,"end":122,"token_start":19,"token_end":19,"label":"DRUG"},{"start":142,"end":153,"token_start":26,"token_end":26,"label":"DRUG"}],"_input_hash":1244089381,"_task_hash":-1525920106,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":19,"child":26,"head_span":{"start":112,"end":122,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":142,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Exenatide 2 mg weekly and liraglutide 1.8 mg daily reduced HbA1c by more than exenatide 10 \u03bcg twice daily and sitagliptin 100 mg daily .","paragraph":"<h3><u>Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.</u></h3>Studies were mostly of short duration, usually 26 weeks. All GLP-1 agonists reduced HbA1c by about 1% compared to placebo. Exenatide twice daily and insulin gave similar reductions in HbA1c, but exenatide 2 mg once weekly and <b style='color:Tomato;'><i>liraglutide</i></b> 1.8 mg daily reduced it by 0.20% and 0.30% respectively more than glargine. Liraglutide 1.2 mg daily reduced HbA1c by 0.34% more than <b style='color:Tomato;'><i>sitagliptin</i></b> 100 mg daily. Exenatide and <b style='color:Tomato;'><i>liraglutide</i></b> gave similar improvements in HbA1c to sulphonylureas. <b style='color:DodgerBlue;'><i>Exenatide</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>liraglutide</i></b> <b style='color:DodgerBlue;'><i>1.8</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>HbA1c</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>exenatide</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>\u03bcg</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sitagliptin</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Exenatide 2 mg weekly reduced HbA1c by 0.3% more than <b style='color:Tomato;'><i>pioglitazone</i></b> 45 mg daily.Exenatide and <b style='color:Tomato;'><i>liraglutide</i></b> resulted in greater weight loss (from 2.3 to 5.5 kg) than active comparators. This was not due simply to nausea. Hypoglycaemia was uncommon, except when combined with a sulphonylurea. The commonest adverse events with all GLP-1 agonists were initial nausea and vomiting. The GLP-1 agonists have some effect on beta-cell function, but this is not sustained after the drug is stopped.","tokens":[{"text":"Exenatide","start":0,"end":9,"id":0,"ws":true},{"text":"2","start":9,"end":10,"id":1,"ws":true},{"text":"mg","start":11,"end":13,"id":2,"ws":true},{"text":"weekly","start":14,"end":20,"id":3,"ws":true},{"text":"and","start":21,"end":24,"id":4,"ws":true},{"text":"liraglutide","start":25,"end":36,"id":5,"ws":true},{"text":"1.8","start":37,"end":40,"id":6,"ws":true},{"text":"mg","start":41,"end":43,"id":7,"ws":true},{"text":"daily","start":44,"end":49,"id":8,"ws":true},{"text":"reduced","start":50,"end":57,"id":9,"ws":true},{"text":"HbA1c","start":58,"end":63,"id":10,"ws":true},{"text":"by","start":64,"end":66,"id":11,"ws":true},{"text":"more","start":67,"end":71,"id":12,"ws":true},{"text":"than","start":72,"end":76,"id":13,"ws":true},{"text":"exenatide","start":77,"end":86,"id":14,"ws":true},{"text":"10","start":87,"end":89,"id":15,"ws":true},{"text":"\u03bcg","start":90,"end":92,"id":16,"ws":true},{"text":"twice","start":93,"end":98,"id":17,"ws":true},{"text":"daily","start":99,"end":104,"id":18,"ws":true},{"text":"and","start":105,"end":108,"id":19,"ws":true},{"text":"sitagliptin","start":109,"end":120,"id":20,"ws":true},{"text":"100","start":121,"end":124,"id":21,"ws":true},{"text":"mg","start":125,"end":127,"id":22,"ws":true},{"text":"daily","start":128,"end":133,"id":23,"ws":true},{"text":".","start":134,"end":135,"id":24,"ws":false}],"spans":[{"start":25,"end":36,"token_start":5,"token_end":5,"label":"DRUG"},{"start":109,"end":120,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1249903222,"_task_hash":-1554071902,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"One group ( 31 patients ) was treated with capecitabine alone , and another group was treated with capecitabine plus thalidomide .","paragraph":"<h3><u>[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].</u></h3>Sixty-one patients with unresectable or metastatic PC who had progressed on single-agent Gem or a Gem-containing regimen were enrolled. The patients were randomly divided into two groups. <b style='color:DodgerBlue;'><i>One</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>31</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>another</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Capecitabine was administered orally twice a day at a dose of 1, 250 mg/m(2) for 14-day followed by 7-day rest and oral <b style='color:Tomato;'><i>thalidomide</i></b> 100 mg was given daily without interruption until disease progression or occurrence of unacceptable toxicity.","tokens":[{"text":"One","start":0,"end":3,"id":0,"ws":true},{"text":"group","start":3,"end":8,"id":1,"ws":true},{"text":"(","start":9,"end":10,"id":2,"ws":true},{"text":"31","start":11,"end":13,"id":3,"ws":true},{"text":"patients","start":14,"end":22,"id":4,"ws":true},{"text":")","start":23,"end":24,"id":5,"ws":true},{"text":"was","start":25,"end":28,"id":6,"ws":true},{"text":"treated","start":29,"end":36,"id":7,"ws":true},{"text":"with","start":37,"end":41,"id":8,"ws":true},{"text":"capecitabine","start":42,"end":54,"id":9,"ws":true},{"text":"alone","start":55,"end":60,"id":10,"ws":true},{"text":",","start":61,"end":62,"id":11,"ws":true},{"text":"and","start":63,"end":66,"id":12,"ws":true},{"text":"another","start":67,"end":74,"id":13,"ws":true},{"text":"group","start":75,"end":80,"id":14,"ws":true},{"text":"was","start":81,"end":84,"id":15,"ws":true},{"text":"treated","start":85,"end":92,"id":16,"ws":true},{"text":"with","start":93,"end":97,"id":17,"ws":true},{"text":"capecitabine","start":98,"end":110,"id":18,"ws":true},{"text":"plus","start":111,"end":115,"id":19,"ws":true},{"text":"thalidomide","start":116,"end":127,"id":20,"ws":true},{"text":".","start":128,"end":129,"id":21,"ws":false}],"spans":[{"start":42,"end":54,"token_start":9,"token_end":9,"label":"DRUG"},{"start":98,"end":110,"token_start":18,"token_end":18,"label":"DRUG"},{"start":116,"end":127,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1784487108,"_task_hash":-982774450,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":18,"child":20,"head_span":{"start":98,"end":110,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":116,"end":127,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB11","COMB1T0"],"answer":"accept"}
{"text":"[ Clinical study of the efficacy and tolerability of nimesulide in suppositories compared to flurbiprofen in gynecology ] .","paragraph":"<h3><u>[Clinical study of the efficacy and tolerability of nimesulide in suppositories compared to flurbiprofen in gynecology].</u></h3> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tolerability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nimesulide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>suppositories</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>flurbiprofen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>gynecology</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The efficacy and tolerability of <b style='color:Tomato;'><i>nimesulide</i></b> in a new pharmaceutical suppository form were assessed in a double blind study versus <b style='color:Tomato;'><i>flurbiprofen</i></b> in pain-inflammatory pathologies of obstetrico-gynecological nature. One hundred patients with pelvic inflammatory disease were randomly assigned to treatment with <b style='color:Tomato;'><i>nimesulide</i></b> or <b style='color:Tomato;'><i>flurbiprofen</i></b>. Both drugs, administered in a dose of 2 suppositories a day for 7 days, evidenced speedy, effective analgesic and anti-inflammatory activity combined with good tolerability. Specifically, as regards the pain component, <b style='color:Tomato;'><i>nimesulide</i></b> demonstrated a significantly more marked analgesic effect than <b style='color:Tomato;'><i>flurbiprofen</i></b> in the first two hours of treatment.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Clinical","start":1,"end":9,"id":1,"ws":true},{"text":"study","start":10,"end":15,"id":2,"ws":true},{"text":"of","start":16,"end":18,"id":3,"ws":true},{"text":"the","start":19,"end":22,"id":4,"ws":true},{"text":"efficacy","start":23,"end":31,"id":5,"ws":true},{"text":"and","start":32,"end":35,"id":6,"ws":true},{"text":"tolerability","start":36,"end":48,"id":7,"ws":true},{"text":"of","start":49,"end":51,"id":8,"ws":true},{"text":"nimesulide","start":52,"end":62,"id":9,"ws":true},{"text":"in","start":63,"end":65,"id":10,"ws":true},{"text":"suppositories","start":66,"end":79,"id":11,"ws":true},{"text":"compared","start":80,"end":88,"id":12,"ws":true},{"text":"to","start":89,"end":91,"id":13,"ws":true},{"text":"flurbiprofen","start":92,"end":104,"id":14,"ws":true},{"text":"in","start":105,"end":107,"id":15,"ws":true},{"text":"gynecology","start":108,"end":118,"id":16,"ws":true},{"text":"]","start":119,"end":120,"id":17,"ws":true},{"text":".","start":121,"end":122,"id":18,"ws":false}],"spans":[{"start":52,"end":62,"token_start":9,"token_end":9,"label":"DRUG"},{"start":92,"end":104,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":839153066,"_task_hash":955287872,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The conditioning regimen consisted of busulfan 150 mg/m2/day for 4 days and thiotepa 300 mg/m2/day for the 3 following days .","paragraph":"<h3><u>A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.</u></h3>Sixteen children with refractory or relapsed ependymoma were entered in a phase-II study of high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>conditioning</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>busulfan</i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>mg/m2/day</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>thiotepa</i></b> <b style='color:DodgerBlue;'><i>300</i></b> <b style='color:DodgerBlue;'><i>mg/m2/day</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients had previously been treated by surgery and conventional chemotherapy. Eight of them had also received irradiation at doses ranging from 45 to 55 Gy at the tumor site. At the time of transplantation, 9 patients were in first relapse, 5 in second relapse and 2 in third relapse or more; all had measurable disease; 15 patients were evaluable for response. No radiologic response > 50% was observed. Stable disease and progressive disease were documented in 10 and 5 cases, respectively. The duration of response to this treatment, which lasted for a median time of 7 months (range: 5-8 months), was only evaluable in 5 patients who did not receive further treatment after ABMT. To date, there are 3 disease-free survivors at 15, 25 and 27 months all of whom were treated with second complete surgical resection and local radiotherapy (55 Gy). Toxicity was severe, mainly digestive and cutaneous, and 1 toxicity-related death occurred. Unlike medulloblastomas, ependymomas do not appear to be sensitive to this combination therapy. New therapeutic approaches are warranted.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"conditioning","start":3,"end":15,"id":1,"ws":true},{"text":"regimen","start":16,"end":23,"id":2,"ws":true},{"text":"consisted","start":24,"end":33,"id":3,"ws":true},{"text":"of","start":34,"end":36,"id":4,"ws":true},{"text":"busulfan","start":37,"end":45,"id":5,"ws":true},{"text":"150","start":46,"end":49,"id":6,"ws":true},{"text":"mg/m2/day","start":50,"end":59,"id":7,"ws":true},{"text":"for","start":60,"end":63,"id":8,"ws":true},{"text":"4","start":64,"end":65,"id":9,"ws":true},{"text":"days","start":66,"end":70,"id":10,"ws":true},{"text":"and","start":71,"end":74,"id":11,"ws":true},{"text":"thiotepa","start":75,"end":83,"id":12,"ws":true},{"text":"300","start":84,"end":87,"id":13,"ws":true},{"text":"mg/m2/day","start":88,"end":97,"id":14,"ws":true},{"text":"for","start":98,"end":101,"id":15,"ws":true},{"text":"the","start":102,"end":105,"id":16,"ws":true},{"text":"3","start":106,"end":107,"id":17,"ws":true},{"text":"following","start":108,"end":117,"id":18,"ws":true},{"text":"days","start":118,"end":122,"id":19,"ws":true},{"text":".","start":123,"end":124,"id":20,"ws":false}],"spans":[{"start":37,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":75,"end":83,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":1910763099,"_task_hash":-108590683,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":37,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":75,"end":83,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11","NEG1T1"],"answer":"accept"}
{"text":"When given separately , both captopril and digoxin decreased the pulmonary capillary wedge pressure by , respectively , 24 % ( p = 0.003 ) and 34 % ( p = 0.004 ) and systemic vascular resistance by 23 % ( p = 0.09 ) and 20 % ( p = 0.03 ) .","paragraph":"<h3><u>Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure.</u></h3>The effects of intravenous <b style='color:Tomato;'><i>captopril</i></b> and intravenous <b style='color:Tomato;'><i>digoxin</i></b> given separately and in combination on rest and exercise hemodynamics were studied in 16 patients with severe heart failure and sinus rhythm. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>separately</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>digoxin</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>capillary</i></b> <b style='color:DodgerBlue;'><i>wedge</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.003</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>34</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.004</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>23</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.09</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.03</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Only <b style='color:Tomato;'><i>digoxin</i></b> increased cardiac index by 23% (p = 0.03) and stroke work index by 52% (p = 0.01). During maximal exercise, <b style='color:Tomato;'><i>captopril</i></b> alone decreased systemic vascular resistance by 28% (p = 0.0002) and increased cardiac index by 33% (p = 0.02). Digoxin alone decreased pulmonary capillary wedge pressure by 11% (p = 0.04) and increased stroke work index by 44% (p = 0.01). The combination of <b style='color:Tomato;'><i>captopril</i></b> and <b style='color:Tomato;'><i>digoxin</i></b> resulted in a decrease in pulmonary capillary wedge pressure and systemic vascular resistance and an increase in cardiac index and stroke work index both at rest and during exercise that was greater than values observed with either drug given alone. Cardiac index response to the combination of <b style='color:Tomato;'><i>captopril</i></b> and <b style='color:Tomato;'><i>digoxin</i></b> correlated with baseline serum aldosterone concentration (r = 0.81, p less than 0.001) and plasma renin activity (r = 0.74, p less than 0.0002). A significant decrease in nor<b style='color:Tomato;'><i>epinephrine</i></b> concentration was noted after <b style='color:Tomato;'><i>digoxin</i></b> was administered alone or added to <b style='color:Tomato;'><i>captopril</i></b>. These findings demonstrate that in patients with severe heart failure, the acute administration of <b style='color:Tomato;'><i>captopril</i></b> and <b style='color:Tomato;'><i>digoxin</i></b> has an independent salutary hemodynamic effect. The combination of these agents, however, has an adjunctive effect on cardiac function at rest and during exercise.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"given","start":4,"end":9,"id":1,"ws":true},{"text":"separately","start":10,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"both","start":23,"end":27,"id":4,"ws":true},{"text":"captopril","start":28,"end":37,"id":5,"ws":true},{"text":"and","start":38,"end":41,"id":6,"ws":true},{"text":"digoxin","start":42,"end":49,"id":7,"ws":true},{"text":"decreased","start":50,"end":59,"id":8,"ws":true},{"text":"the","start":60,"end":63,"id":9,"ws":true},{"text":"pulmonary","start":64,"end":73,"id":10,"ws":true},{"text":"capillary","start":74,"end":83,"id":11,"ws":true},{"text":"wedge","start":84,"end":89,"id":12,"ws":true},{"text":"pressure","start":90,"end":98,"id":13,"ws":true},{"text":"by","start":99,"end":101,"id":14,"ws":true},{"text":",","start":102,"end":103,"id":15,"ws":true},{"text":"respectively","start":104,"end":116,"id":16,"ws":true},{"text":",","start":117,"end":118,"id":17,"ws":true},{"text":"24","start":119,"end":121,"id":18,"ws":true},{"text":"%","start":122,"end":123,"id":19,"ws":true},{"text":"(","start":124,"end":125,"id":20,"ws":true},{"text":"p","start":126,"end":127,"id":21,"ws":true},{"text":"=","start":128,"end":129,"id":22,"ws":true},{"text":"0.003","start":130,"end":135,"id":23,"ws":true},{"text":")","start":136,"end":137,"id":24,"ws":true},{"text":"and","start":138,"end":141,"id":25,"ws":true},{"text":"34","start":142,"end":144,"id":26,"ws":true},{"text":"%","start":145,"end":146,"id":27,"ws":true},{"text":"(","start":147,"end":148,"id":28,"ws":true},{"text":"p","start":149,"end":150,"id":29,"ws":true},{"text":"=","start":151,"end":152,"id":30,"ws":true},{"text":"0.004","start":153,"end":158,"id":31,"ws":true},{"text":")","start":159,"end":160,"id":32,"ws":true},{"text":"and","start":161,"end":164,"id":33,"ws":true},{"text":"systemic","start":165,"end":173,"id":34,"ws":true},{"text":"vascular","start":174,"end":182,"id":35,"ws":true},{"text":"resistance","start":183,"end":193,"id":36,"ws":true},{"text":"by","start":194,"end":196,"id":37,"ws":true},{"text":"23","start":197,"end":199,"id":38,"ws":true},{"text":"%","start":200,"end":201,"id":39,"ws":true},{"text":"(","start":202,"end":203,"id":40,"ws":true},{"text":"p","start":204,"end":205,"id":41,"ws":true},{"text":"=","start":206,"end":207,"id":42,"ws":true},{"text":"0.09","start":208,"end":212,"id":43,"ws":true},{"text":")","start":213,"end":214,"id":44,"ws":true},{"text":"and","start":215,"end":218,"id":45,"ws":true},{"text":"20","start":219,"end":221,"id":46,"ws":true},{"text":"%","start":222,"end":223,"id":47,"ws":true},{"text":"(","start":224,"end":225,"id":48,"ws":true},{"text":"p","start":226,"end":227,"id":49,"ws":true},{"text":"=","start":228,"end":229,"id":50,"ws":true},{"text":"0.03","start":230,"end":234,"id":51,"ws":true},{"text":")","start":235,"end":236,"id":52,"ws":true},{"text":".","start":237,"end":238,"id":53,"ws":false}],"spans":[{"start":28,"end":37,"token_start":5,"token_end":5,"label":"DRUG"},{"start":42,"end":49,"token_start":7,"token_end":7,"label":"DRUG"}],"_input_hash":-432763942,"_task_hash":521665041,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"All patients received paclitaxel 200mg/m(2 ) as a continuous 3-hour infusion followed by carboplatin calculated using the Calvert formula for a target AUC of 6 mg / ( ml min ) , every 21 days for a maximum of eight cycles .","paragraph":"<h3><u>Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.</u></h3>Seventy-five chemotherapy-naive patients with stage IIIB-IV NSCLC were randomly assigned to BMS-275291 or placebo. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>200mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>3-hour</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>calculated</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Calvert</i></b> <b style='color:DodgerBlue;'><i>formula</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>/</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ml</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>eight</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> BMS-275291 or placebo was administered on an outpatient basis at a daily oral dosage of 1200 mg.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"received","start":12,"end":20,"id":2,"ws":true},{"text":"paclitaxel","start":21,"end":31,"id":3,"ws":true},{"text":"200mg/m(2","start":32,"end":41,"id":4,"ws":true},{"text":")","start":42,"end":43,"id":5,"ws":true},{"text":"as","start":44,"end":46,"id":6,"ws":true},{"text":"a","start":47,"end":48,"id":7,"ws":true},{"text":"continuous","start":49,"end":59,"id":8,"ws":true},{"text":"3-hour","start":60,"end":66,"id":9,"ws":true},{"text":"infusion","start":67,"end":75,"id":10,"ws":true},{"text":"followed","start":76,"end":84,"id":11,"ws":true},{"text":"by","start":85,"end":87,"id":12,"ws":true},{"text":"carboplatin","start":88,"end":99,"id":13,"ws":true},{"text":"calculated","start":100,"end":110,"id":14,"ws":true},{"text":"using","start":111,"end":116,"id":15,"ws":true},{"text":"the","start":117,"end":120,"id":16,"ws":true},{"text":"Calvert","start":121,"end":128,"id":17,"ws":true},{"text":"formula","start":129,"end":136,"id":18,"ws":true},{"text":"for","start":137,"end":140,"id":19,"ws":true},{"text":"a","start":141,"end":142,"id":20,"ws":true},{"text":"target","start":143,"end":149,"id":21,"ws":true},{"text":"AUC","start":150,"end":153,"id":22,"ws":true},{"text":"of","start":154,"end":156,"id":23,"ws":true},{"text":"6","start":157,"end":158,"id":24,"ws":true},{"text":"mg","start":159,"end":161,"id":25,"ws":true},{"text":"/","start":162,"end":163,"id":26,"ws":true},{"text":"(","start":164,"end":165,"id":27,"ws":true},{"text":"ml","start":166,"end":168,"id":28,"ws":true},{"text":"min","start":169,"end":172,"id":29,"ws":true},{"text":")","start":173,"end":174,"id":30,"ws":true},{"text":",","start":175,"end":176,"id":31,"ws":true},{"text":"every","start":177,"end":182,"id":32,"ws":true},{"text":"21","start":183,"end":185,"id":33,"ws":true},{"text":"days","start":186,"end":190,"id":34,"ws":true},{"text":"for","start":191,"end":194,"id":35,"ws":true},{"text":"a","start":195,"end":196,"id":36,"ws":true},{"text":"maximum","start":197,"end":204,"id":37,"ws":true},{"text":"of","start":205,"end":207,"id":38,"ws":true},{"text":"eight","start":208,"end":213,"id":39,"ws":true},{"text":"cycles","start":214,"end":220,"id":40,"ws":true},{"text":".","start":221,"end":222,"id":41,"ws":false}],"spans":[{"start":21,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},{"start":88,"end":99,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":292068810,"_task_hash":1338798503,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":13,"child":3,"head_span":{"start":88,"end":99,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":21,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB11","COMB1T1"],"answer":"accept"}
{"text":"Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration .","paragraph":"<h3><u>Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.</u></h3> <b style='color:MediumOrchid;'><i>Verteporfin</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>triamcinolone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>types</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>choroidal</i></b> <b style='color:DodgerBlue;'><i>neovascularization</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>age-related</i></b> <b style='color:DodgerBlue;'><i>macular</i></b> <b style='color:DodgerBlue;'><i>degeneration</i></b> <b style='color:DodgerBlue;'><i>.</i></b> To evaluate the efficacy and safety of photodynamic therapy with <b style='color:Tomato;'><i>verteporfin</i></b> combined with intravitreal <b style='color:Tomato;'><i>triamcinolone</i></b> in choroidal neovascularization secondary to age-related macular degeneration (AMD).","tokens":[{"text":"Verteporfin","start":0,"end":11,"id":0,"ws":true},{"text":"therapy","start":11,"end":18,"id":1,"ws":true},{"text":"combined","start":19,"end":27,"id":2,"ws":true},{"text":"with","start":28,"end":32,"id":3,"ws":true},{"text":"intravitreal","start":33,"end":45,"id":4,"ws":true},{"text":"triamcinolone","start":46,"end":59,"id":5,"ws":true},{"text":"in","start":60,"end":62,"id":6,"ws":true},{"text":"all","start":63,"end":66,"id":7,"ws":true},{"text":"types","start":67,"end":72,"id":8,"ws":true},{"text":"of","start":73,"end":75,"id":9,"ws":true},{"text":"choroidal","start":76,"end":85,"id":10,"ws":true},{"text":"neovascularization","start":86,"end":104,"id":11,"ws":true},{"text":"due","start":105,"end":108,"id":12,"ws":true},{"text":"to","start":109,"end":111,"id":13,"ws":true},{"text":"age-related","start":112,"end":123,"id":14,"ws":true},{"text":"macular","start":124,"end":131,"id":15,"ws":true},{"text":"degeneration","start":132,"end":144,"id":16,"ws":true},{"text":".","start":145,"end":146,"id":17,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":46,"end":59,"token_start":5,"token_end":5,"label":"DRUG"}],"_input_hash":-915062988,"_task_hash":415283726,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":0,"child":5,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":46,"end":59,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB11","COMB1T0"],"answer":"accept"}
{"text":"The Gynecologic Oncology Group has conducted a series of phase II studies with ifosfamide and mesna since 1985 .","paragraph":"<h3><u>Gynecologic Oncology Group studies with ifosfamide.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>Gynecologic</i></b> <b style='color:DodgerBlue;'><i>Oncology</i></b> <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>series</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mesna</i></b> <b style='color:DodgerBlue;'><i>since</i></b> <b style='color:DodgerBlue;'><i>1985</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Previously untreated patients received <b style='color:Tomato;'><i>ifosfamide</i></b> 1.5 g/m2 intravenously daily for 5 days. Mesna was given intravenously every 4 hours three times daily at 20% of the daily <b style='color:Tomato;'><i>ifosfamide</i></b> dose. Because of the toxic effects observed in previously treated patients with ovarian cancer, the <b style='color:Tomato;'><i>ifosfamide</i></b> dose was reduced to 1.2 g/m2/d in patients with prior chemotherapy or radiotherapy. In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses. In patients with squamous carcinoma of the cervix, an 11.1% response rate (three of 27 patients) was observed in those who had received prior platinum therapy. In 51 previously untreated patients, the response rate was 15.7%. In nonsquamous cervical carcinomas, there were three partial responses among 25 patients (12%). An 8.6% response rate was observed among 23 patients with previously treated endometrial adenocarcinomas. In uterine sarcomas, response rates were 30.7% in mixed m\u00fcllerian tumors, 17.2% in leiomyosarcomas, and 27.3% in endometrial stromal sarcomas. Patients with ovarian sarcomas responded in 27.8% of cases. Studies with <b style='color:Tomato;'><i>ifosfamide</i></b> combinations are currently under way by the Gynecologic Oncology Group.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"Gynecologic","start":3,"end":14,"id":1,"ws":true},{"text":"Oncology","start":15,"end":23,"id":2,"ws":true},{"text":"Group","start":24,"end":29,"id":3,"ws":true},{"text":"has","start":30,"end":33,"id":4,"ws":true},{"text":"conducted","start":34,"end":43,"id":5,"ws":true},{"text":"a","start":44,"end":45,"id":6,"ws":true},{"text":"series","start":46,"end":52,"id":7,"ws":true},{"text":"of","start":53,"end":55,"id":8,"ws":true},{"text":"phase","start":56,"end":61,"id":9,"ws":true},{"text":"II","start":62,"end":64,"id":10,"ws":true},{"text":"studies","start":65,"end":72,"id":11,"ws":true},{"text":"with","start":73,"end":77,"id":12,"ws":true},{"text":"ifosfamide","start":78,"end":88,"id":13,"ws":true},{"text":"and","start":89,"end":92,"id":14,"ws":true},{"text":"mesna","start":93,"end":98,"id":15,"ws":true},{"text":"since","start":99,"end":104,"id":16,"ws":true},{"text":"1985","start":105,"end":109,"id":17,"ws":true},{"text":".","start":110,"end":111,"id":18,"ws":false}],"spans":[{"start":78,"end":88,"token_start":13,"token_end":13,"label":"DRUG"},{"start":93,"end":98,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":-163435819,"_task_hash":-929678174,"_session_id":"drug_drug_yosi-yosi","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":78,"end":88,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":93,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB11","COMB1T0"],"answer":"accept"}
